New ASCO Guideline on Second-Line Hormone Therapy in Prostate Cancer

The American Society of Clinical Oncology (ASCO) issued the first guidance, a provisional clinical opinion (PCO), on second-line hormonal therapy for chemotherapy-naive castration-resistant prostate cancer (CRPC). Today we are speaking about the guideline with one of its authors, Eric Singer, MD, a urologic oncologist at Rutgers Cancer Institute of New Jersey. —Interviewed by Anna Azvolinsky

Source: CancerNetwork - July 26, 2017 Category: Cancer & Oncology Authors: Eric Singer, MD Tags: Genitourinary Cancers Q & Prostate Cancer Source Type: news